Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEDZ-K: Open-label study of SZC in pediatric hyperkalaemia
jRCT2031220173Recruiting
- Sponsor
- AstraZeneca
- Start
- Jul 2022
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
Open-label, single-arm trial of sodium zirconium cyclosilicate in hyperkalemia, sponsored by AstraZeneca. Primary endpoints: Correction phase normokalemia achievement and Maintenance phase normokalemia maintenance. Started Jul 2022; status: recruiting.
02
Drugs
sodium zirconium cyclosilicate
03
Conditions
hyperkalemia
Beyond the preview
Go deeper on jRCT2031220173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220173.